|
Post by falconquest on Feb 15, 2017 19:22:38 GMT -5
I asked why and explained I was on it and loved it. He stated his patients were too young and it causes pulmonary disease in young ones. I must have had a puzzled looked on my face as he reminded me he treated children. I then reminded him he also treated 18 and 19 year olds, which are not children. I was a little taken back by his abruptness and inability to separate the fact he treats infants to adults (though in peds). How can they get away with this? Unfortunately this may be the way this whole story plays out. A few users "get it" but most doctors are too entrenched in their thinking to prescribe. Imagine a small Biotech developing a cure for cancer but it has a novel delivery system. First, BP's would shoot it down and then doctors would be reluctant to prescribe. Mannkind may have a long road ahead of them (if they can last that long).
|
|
|
Post by sayhey24 on Feb 15, 2017 22:09:14 GMT -5
Easy - The BP sales guys have done a great job of spreading FUD while no one has every explained to the doctors what afrezza is. The BP guys went out on the offense and Sanofi pulled back. The good news is afrezza really is as good as we think it is and really can mimic a healthy pancreas. Now, our new sales team needs to get the word out and be persistent. They need an answer for all this FUD. Its out there in studies. It may be helpful to have Peppy and others put these studies all together in the resource area so the sales guys have a starting place to look. Things like all the intensive insulin studies; studies on inert dusk inhalation, time in zone vs A1c, etc. Those doctors that are not willing to learn about new treatment options should soon be replaced by AI, like IBM's Walston. Hmmm - I think you just stated Onduo's business model. Now we see in DiabetesMine Mike C. talking about selling direct over the internet. Lets see, Ondou with it's cloud monitoring, personalized modeling and dosing recommendation for PWDs over the net along with Teledoc like services over the net. Oscar insurance an Onduo partner looking to offer cut-rate prices for clients using these Teledoc like internet services writing prescriptions over the net potentially going direct to MNKD for fulfillment. Trump in the Whitehouse while his son-in-law's brother is Oscar's founder looking to let insurance companies sell across state lines. These Cloud services are great for that cross-state model. Who knows, I have seen crazier things work out.
|
|
|
Post by peppy on Feb 15, 2017 22:57:47 GMT -5
at this point, it looks like we will need the teledocs. If that is the case start the commercial advertisement.
|
|
|
Post by surplusvalue on Feb 15, 2017 23:15:34 GMT -5
Those doctors that are not willing to learn about new treatment options should soon be replaced by AI, like IBM's Walston. Hmmm - I think you just stated Onduo's business model. Now we see in DiabetesMine Mike C. talking about selling direct over the internet. Lets see, Ondou with it's cloud monitoring, personalized modeling and dosing recommendation for PWDs over the net along with Teledoc like services over the net. Oscar insurance an Onduo partner looking to offer cut-rate prices for clients using these Teledoc like internet services writing prescriptions over the net potentially going direct to MNKD for fulfillment. Trump in the Whitehouse while his son-in-law's brother is Oscar's founder looking to let insurance companies sell across state lines. These Cloud services are great for that cross-state model. Who knows, I have seen crazier things work out. Looks like this thread has come full circle with the original poster calling for MNKD to do something differently than big pharma. Your musings here are consistent with what I reiterated about what AL said about taking care of the patient first ( I added instead of the doctors). Selling direct using the technology would sure throw big pharmas probable use of technology to bypass Afrezza (which I suggested is their intention in a previous thread discussion we had about this monitoring technology) for a loop. It would not only allow MNKD to deal with the conservatism of endos but it would bring to full realization that the endos are threatened by Afrezza (as you suggested a long time ago). If MNKD goes at it again and comes up with the same results with the new sales team and even after advertising this might be a viable alternative. Then any advertising employed in this new approach would really be DTC, wouldnt it ! With a disruptive product, a disruptive approach may be exactly what is needed. Is MNKD management forward thinking enough? Let's hope so. This would be very rad as they used to say on the west coast.
|
|
|
Post by sayhey24 on Feb 16, 2017 7:38:39 GMT -5
Hmmm - I think you just stated Onduo's business model. Now we see in DiabetesMine Mike C. talking about selling direct over the internet. Lets see, Ondou with it's cloud monitoring, personalized modeling and dosing recommendation for PWDs over the net along with Teledoc like services over the net. Oscar insurance an Onduo partner looking to offer cut-rate prices for clients using these Teledoc like internet services writing prescriptions over the net potentially going direct to MNKD for fulfillment. Trump in the Whitehouse while his son-in-law's brother is Oscar's founder looking to let insurance companies sell across state lines. These Cloud services are great for that cross-state model. Who knows, I have seen crazier things work out. Looks like this thread has come full circle with the original poster calling for MNKD to do something differently than big pharma. Your musings here are consistent with what I reiterated about what AL said about taking care of the patient first ( I added instead of the doctors). Selling direct using the technology would sure throw big pharmas probable use of technology to bypass Afrezza (which I suggested is their intention in a previous thread discussion we had about this monitoring technology) for a loop. It would not only allow MNKD to deal with the conservatism of endos but it would bring to full realization that the endos are threatened by Afrezza (as you suggested a long time ago). If MNKD goes at it again and comes up with the same results with the new sales team and even after advertising this might be a viable alternative. Then any advertising employed in this new approach would really be DTC, wouldnt it ! With a disruptive product, a disruptive approach may be exactly what is needed. Is MNKD management forward thinking enough? Let's hope so. This would be very rad as they used to say on the west coast. Yes - we have come full circle and I don't like going in circles. I put the open letter for the new sales team together the other day which seems to have gotten some interesting traction. Maybe tonight I will put a business sketch-plan together. MNKD is starting to get things together; insurance; website; and the front line sales team. But, I have no confidence most Endos will subscribe until forced to. Would Macy's have ever put a website together if it were not for the Amazon(s) and now its Macy's closing many of their stores. Here we have doctors giving metfromin and Glipizide to PWDs because the metformin in no longer good enough and the PWD are now getting hypos, no kidding. Then the PWD asks for afrezza and they tell the PWD no way its too dangerous. This has just got to stop.
|
|
|
Post by MnkdWASmyRtrmntPlan on Feb 16, 2017 8:31:22 GMT -5
... I put the open letter for the new sales team together the other day which seems to have gotten some interesting traction. Maybe tonight I will put a business sketch-plan together. ... Seyhey, I meant to compliment your open letter. I always enjoy reading your posts. I appreciate your knowledge and insight and I hope you are able to create your business sketch plan. I look forward to reading it.
|
|